Autosomal dominant polycystic kidney disease (ADPKD) is a rare genetic disorder characterized by progressive cyst formation. Emerging evidence suggests that histone deacetylase 6 (HDAC6) plays a pivotal role in the regulation of disease progression. In this study, a series of quinazoli-4-one derivatives were designed and synthesized, among which compound 6a (GV-001) exhibited superior potency and selectivity in both enzyme inhibition (IC50 = 1.18 nM) and immunoblotting assays. Subsequent analysis using the BioMAP fibrosis panel and an in vitro human kidney cyst model revealed that GV-001 mitigates inflammatory and fibrotic markers, such as sIL-6 and Collagen I, while effectively suppressing cyst growth. Additionally, GV-001 displayed favorable oral bioavailability (36%) and kidney exposure (AUC(0–t): 1790 ng·h/mL) in rats, whereas oral administration produced significant therapeutic efficacy in an ADPKD mouse model, along with upregulation of PC1 expression. These results support GV-001 as a promising and selective HDAC6 inhibitor for the treatment of ADPKD.
Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, yet the repertoire of E3 ligase recruiters remains limited. Here, we report the discovery of an aldehyde-anchored PROTAC that covalently engages the E3 ligase FBXO22 to induce degradation of the histone methyltransferase NSD2 and CDK12. Competitive electrophile screening identified a phenyl aldehyde warhead as optimal, with SAR studies revealing that degradation is highly sensitive to the steric and electronic environment of the aldehyde moiety. The lead degrader, T9, effectively and selectively induces NSD2 degradation across multiple cancer cell lines. Mechanistic investigations confirmed that degradation is dependent on FBXO22, the ubiquitin-proteasome system, and the neddylation pathway, with mutagenesis identifying Cys326 as the critical residue for covalent engagement. This work establishes a stable covalent ligand for FBXO22, expanding chemical space of PROTAC design by introducing an accessible aldehyde-based E3 ligase ligand with broad potential for protein degradation.
Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, yet the repertoire of E3 ligase recruiters remains limited. Here, we report the discovery of an aldehyde-anchored PROTAC that covalently engages the E3 ligase FBXO22 to induce degradation of the histone methyltransferase NSD2. A phenyl aldehyde warhead was identified as optimal through competitive electrophile screening, and structure–activity relationship studies indicated that degradation is highly sensitive to steric and electronic features surrounding the aldehyde moiety. The optimized degrader, compound T9, effectively induced NSD2 degradation across multiple cancer cell lines, and subsequent mechanistic investigations confirmed that degradation is dependent on FBXO22, the ubiquitin–proteasome system, and the neddylation pathway. Mutagenesis identified Cys326 in the FBXO22 C-terminal domain as critical for activity. Collectively, this work establishes a stable covalent ligand for FBXO22 recruitment and expands the chemical space of PROTAC design by introducing a readily accessible aldehyde-based E3 ligase ligand with broad potential for targeted protein degradation.